Conference Program

Saturday, October 17

2:00 p.m.-4:15 p.m.   Educational Session
                           Convention Level
                           Session Chairperson: Kathleen R. Cho, University of Michigan, Ann Arbor, MI

  2:00 p.m.   The origins of ovarian cancer
               Kathleen R. Cho

  2:45 p.m.   Genomic classification of ovarian cancer
               David D. L. Bowtell, Peter MacCallum Cancer Centre, East Melbourne, Australia

  3:30 p.m.   Primer on tumor immunology
               Daniel J. Powell, University of Pennsylvania, Philadelphia, PA

4:15 p.m.-5:30 p.m.   Break
                           Florida Ballroom Prefunction

5:30 p.m.-7:30 p.m.   Opening Keynote Session
                           Convention Level
                           Session Chairperson: Benjamin G. Neel, Perlmutter Cancer Center, New York University Langone Medical Center, New York, NY

  5:30 p.m.   Targeting DNA repair in ovarian cancer therapy
               Alan D. D’Andrea, Dana-Farber Cancer Institute, Boston, MA

  6:30 p.m.   One carbon metabolism and cancer
               Karen H. Vousden, Beatson Institute for Cancer Research, Glasgow, United Kingdom

7:30 p.m.-9:30 p.m.   Opening Reception
                           Upper Pool Deck
Sunday, October 18

7:00 a.m.-8:00 a.m.  Continental Breakfast and Mentoring Roundtables  
Plaza International Ballroom G

8:00 a.m.-10:00 a.m.  Plenary Session 1: DNA Damage and Homologous Recombination  
Convention Level  
Session Chairperson: Daniel Durocher, Lunenfeld-Tanenbaum Research Institute, Toronto, ON, Canada

8:00 a.m.  Regulation of BRCA1- and BRCA2-dependent DNA repair  
Daniel Durocher

8:30 a.m.  Targeting checkpoint signaling and DNA repair in ovarian cancer  
Larry M. Karnitz, Mayo Clinic, Rochester, MN

9:00 a.m.  PI3K- and PARP-inhibitors for the treatment of women cancers  
Gerburg M. Wulf, Beth Israel Deaconess Medical Center, Boston, MA

9:30 a.m.  EMSY impairs DNA damage repair in a phosphorylation-dependent manner*  
Petar Jelinic, Memorial Sloan Kettering Cancer Center, New York, NY

9:45 a.m.  Identification of germline and somatic alterations in homologous recombination pathway genes in high-grade ovarian carcinomas and response to the PARP inhibitor rucaparib in ARIEL2*  
Elizabeth Swisher, University of Washington School of Medicine, Seattle, WA

10:00 a.m.-10:30 a.m.  Break  
Florida Ballroom Prefunction

10:30 a.m.-12:30 p.m.  Plenary Session 2: Immunotherapy for Ovarian Cancer  
Convention Level  
Session Chairperson: Pamela S. Ohashi, Princess Margaret Cancer Centre, Toronto, ON, Canada

10:30 a.m.  Reprogramming T cells for adoptive immunotherapy of ovarian cancer  
Kunle Odunsi, Roswell Park Cancer Institute, Buffalo, NY

11:00 a.m.  Regulatory innate lymphoid cells suppress antitumor T cells  
Pamela S. Ohashi

11:30 a.m.  Deciphering the immunobiology of ovarian cancer to create effective immunotherapy  
Daniel J. Powell, University of Pennsylvania, Philadelphia, PA

12:00 p.m.  Combinatorial blockade of PD-1, CTLA-4, and LAG-3 pathways inhibits murine ovarian tumor growth*  
Ruea-Yea Huang, Roswell Park Cancer Institute, Buffalo, NY

12:15 p.m.  Epigenetic treatment of ovarian cancer cells increases immune cell recruitment to the tumor microenvironment: Implications for response to immune checkpoint therapy*  
Meredith Stone, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
12:30 p.m.-2:30 p.m.  Lunch on Own

2:30 p.m.-3:30 p.m.  Panel Discussion: Patient Experiences with Decision Making, Including Clinical Trials  
Convention Level  
Session Moderator: Douglas A. Levine, Memorial Sloan Kettering Cancer Center, New York, NY

Panelists:  
Dr. Laura Shawver, The Clearity Foundation, San Diego, CA  
Mrs. Diane O’Connor, Ovarian Cancer Alliance of Oregon and Southwest Washington, Vancouver, WA  
Ms. Carla Jimenez, Cancer Survivor, St. Petersburg, FL  
Dr. James D. Brenton, University of Cambridge, Cambridge, United Kingdom  
Dr. Anil K. Sood, The University of Texas MD Anderson Cancer Center, Houston, TX

3:30 p.m.-5:30 p.m.  Plenary Session 3: Molecular Drivers of Ovarian Cancer (Other than p53)  
Convention Level  
Session Chairperson: David D. L. Bowtell, Peter MacCallum Cancer Centre, East Melbourne, Australia

3:30 p.m.  Determinants of resistance and response in high-grade serous ovarian cancer  
David D. L. Bowtell

4:00 p.m.  Myc, metabolism, and cancer  
Chi V. Dang, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA

4:30 p.m.  The functional genetic architecture of high-grade serous ovarian cancer  
Robert K. Rottapel, Princess Margaret Cancer Centre, Toronto, ON, Canada

5:00 p.m.  Identifying potential targets in Cyclin E-amplified tumors*  
Kai Doberstein, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA

5:15 p.m.  The long noncoding RNA UCA1 regulates mitochondrial activity and Hippo signaling in ovarian cancer*  
Simon Gayther, University of Southern California, Los Angeles, CA

5:30 p.m.-7:30 p.m.  Poster Session A and Reception  
Plaza International Ballroom D-F

*Short talks from proffered papers
Monday, October 19

7:00 a.m.-8:00 a.m. Continental Breakfast and Mentoring Roundtables
Plaza International Ballroom G

8:00 a.m.-10:00 a.m. Plenary Session 4: Non-Serous Ovarian Cancer
Convention Level
Session Chairperson: David G. Huntsman, BC Cancer Foundation, Vancouver, BC, Canada

8:00 a.m. Rarer, yet both interesting and relevant: Other ovarian cancers
David G. Huntsman

8:30 a.m. Endometriosis-related ovarian cancer
Ie-Ming Shih, Johns Hopkins Medical Institutes, Baltimore, MD

9:00 a.m. Molecular characterization of mucinous ovarian carcinoma
Douglas A. Levine, Memorial Sloan Kettering Cancer Center, New York, NY

9:30 a.m. Synchronous ovarian and endometrial carcinomas: The case for pseudo-metastasis*
Michael Anglesio, University of British Columbia, Vancouver, BC, Canada

9:45 a.m. Evidence for extra-ovarian origin and peritoneal metastases that precede ovarian carcinomas in high-grade serous ovarian cancer*
Jeremy Chien, University of Kansas Medical Center, Kansas City, KS

10:00 a.m.-10:30 a.m. Break
Florida Ballroom Prefunction

10:30 a.m.-12:45 p.m. Plenary Session 5: Prevention, Screening, Early Diagnostics, and Epidemiology
Convention Level
Session Chairperson: Nicole D. Urban, Fred Hutchinson Cancer Research Center, Seattle, WA

10:30 a.m. Thinking outside the box: New areas in prevention research
Shelley S. Tworoger, Harvard School of Public Health, Boston, MA

11:00 a.m. Genetic epidemiology of epithelial ovarian cancer: Recent progress and translational potential
Thomas A. Sellers, Moffitt Cancer Center and Research Institute, Tampa, FL

11:30 a.m. Biomarkers for risk prediction, screening, and early diagnostics
Nicole D. Urban

12:00 p.m. Ovarian cancer prevention: Is it time for population screening for BRCA mutations?*
Ian Campbell, Peter MacCallum Cancer Center, East Melbourne, Australia

12:15 p.m. Detection of Müllerian duct carcinomas by lavage of the uterine cavity and mutation analysis: A new concept*
Elisabeth Maritschnegg, Medical University of Vienna, Vienna, Austria

12:30 p.m. Prediagnosis adiposity, physical activity, and ovarian cancer survival*
Adetunji Toriola, Washington University School of Medicine, St. Louis, MO
12:45 p.m.-3:30 p.m.  
**Poster Session B and Lunch**  
Plaza International Ballroom D-F

3:30 p.m.-5:15 p.m.  
**Plenary Session 6: Molecular Driver of Ovarian Cancer: p53**  
Convention Level  
*Session Chairperson: Guillermina Lozano, The University of Texas MD Anderson Cancer Center, Houston, TX*

3:30 p.m.  
**Mutant p53 activities in tumor development**  
Guillermina Lozano

4:00 p.m.  
**Clinical implications of p53 mutation in high-grade serous ovarian cancer**  
James D. Brenton, University of Cambridge, Cambridge, UK

4:30 p.m.  
**Mutant p53 drives early events in fallopian tube tumorigenesis through mesenchyme-associated autocrine production of matrix that supports survival and mesothelial intercalation**  
Marcin Iwanicki, Harvard Medical School, Boston, MA

4:45 p.m.  
**A designed inhibitor of p53 self-aggregation rescues p53 tumor-suppression function in high-grade serous ovarian carcinoma**  
Alice Soragni, University of California, Los Angeles, Los Angeles, CA

5:00 p.m.  
**Exploiting synthetic lethality between the MK2 and p53 pathways with nanotechnology to sensitize ovarian cancer to chemotherapy**  
Yi Wen Kong, Massachusetts Institute of Technology, Cambridge, MA

5:15 p.m.-5:30 p.m.  
**Break**  
Florida Ballroom Prefunction

5:30 p.m.-6:30 p.m.  
**Keynote Plenary Session**  
Convention Level  
*Session Chairperson: Douglas A. Levine, Memorial Sloan Kettering Cancer Center, New York, NY*

**Ovarian cancer screening**  
Usha Menon, University College of London, London, United Kingdom

*Short talks from proffered papers*
Tuesday, October 20

7:00 a.m.-8:00 a.m.   Continental Breakfast and Mentoring Roundtables
                        Plaza International Ballroom G

8:00 a.m.-10:00 a.m.   Plenary Session 7: Modeling Systems for Ovarian Cancer
                        Convention Level
                        Session Chairperson: Ronny I. Drapkin, University of Pennsylvania, Philadelphia, PA

8:00 a.m.  Developing and deploying experimental models systems towards novel drug discovery in ovarian cancer
            Ronny I. Drapkin

8:30 a.m.  Nutritional intervention for prevention of ovarian cancer in a natural model: The laying hen
            Dale Buck Hales, Southern Illinois University School of Medicine, Carbondale, IL

9:00 a.m.  Role of ARID1A in SWI/SNF chromatin remodeling and ovarian cancer
            Ronald Chandler, Michigan State University College of Human Medicine, Grand Rapids, MI

9:30 a.m.  MYC distal enhancers underlie ovarian cancer susceptibility in the 8q24.21 locus*
            Anxhela Gjyshi, Moffitt Cancer Center and Research Institute, Tampa, FL

9:45 a.m.  Computational modeling of serous ovarian carcinoma dynamics: Implications for screening and therapy*
            Shengqing Gu, University of Toronto, Toronto, ON, Canada

10:00 a.m.-10:30 a.m.  Break
                        Florida Ballroom Prefunction
10:30 a.m.-12:30 p.m.  Plenary Session 8: Ovarian Cancer Tumor Microenvironment
Convention Level
Session Chairperson: Anil K. Sood, The University of Texas MD Anderson Cancer Center, Houston, TX

10:30 a.m.  Proteomics reveals a stromal signature of ovarian cancer metastasis
Ernst R. Lengyel, University of Chicago, Chicago, IL

11:00 a.m.  New directions in targeting the tumor microenvironment
Anil K. Sood

11:30 a.m.  EGFL6 and angiocrine factor that regulates cancer cell growth and metastasis
Ronald Buckanovich, University of Michigan, Ann Arbor, MI

12:00 p.m.  Characterization of ascites and tumor-derived ovarian cancer stem-like cells*
Katja Kaipio, University of Turku and Turku University Central Hospital, Turku, Finland

12:15 p.m.  Survival of ARHI-induced dormant autophagic cell death in vivo requires permissive levels of VEGF, IL-8 and IGF-1 in the tumor microenvironment*
Zhen Lu, The University of Texas MD Anderson Cancer Center, Houston, TX

12:30 p.m.-12:45 p.m.  Closing Remarks
Convention Level

*Short talks from proffered papers